The treatment of type 2 diabetes
DOI:
https://doi.org/10.54097/rysqw555Keywords:
Type 2 diabetes, individualized treatment, non-pharmacological therapies, cognitive behavioral therapy, pharmacologic therapies.Abstract
Type 2 diabetes, also known as a long-term metabolic condition contributed to by multiple factors, including insulin resistance, hyperglycemia, and impaired beta-cell function, which can be caused by both genetics and environment. The disease is prevalent globally; it is projected that people who have type 2 diabetes will increase to 552 million by 2030, which emphasizes the importance of developing effective management strategies. The aim of this essay will be to evaluate current treatments for this type of diabetes, including lifestyle interventions (dietary management, intermittent fasting, and so on), non-pharmacological approaches (psychological therapies like cognitive behavioral therapy), and pharmacologic therapies (including both first-line and second-line therapies like metformin, sulfonylurea, DPP2 inhibitors, etc.) by considering their effects and potential risks. The analysis aims to investigate individualized and targeted treatments by considering factors like age, comorbidities, and so on, in order to minimize complications and achieve permanent health in people with type 2 diabetes.
Downloads
References
[1] Damanik, J., & Yunir, E. (2021). Type 2 Diabetes Mellitus and Cognitive Impairment. Acta medica Indonesiana, 53 (2), 213 – 220.
[2] Tinajero, M. G., & Malik, V. S. (2021). An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective. Endocrinology and metabolism clinics of North America, 50 (3), 337 – 355.
[3] Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020). Pathophysiology of Type 2 Diabetes Mellitus. International journal of molecular sciences, 21 (17), 6275.
[4] Chong K, Chang JK, Chuang LM. Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies. Kaohsiung J Med Sci. 2024 Mar; 40 (3): 212 - 220. doi: 10.1002/kjm2.12800. Epub 2024 Jan 6. Syeda, U. S. A., Battillo, D., Visaria, A., & Malin, S. K. (2023). The importance of exercise for glycemic control in type 2 diabetes. American journal of medicine open, 9, 100031.
[5] Syeda, U. S. A., Battillo, D., Visaria, A., & Malin, S. K. (2023). The importance of exercise for glycemic control in type 2 diabetes. American journal of medicine open, 9, 100031.
[6] Cornely, R. M., Subramanya, V., Owen, A., McGee, R. E., & Kulshreshtha, A. (2022). A mixed-methods approach to understanding the perspectives, experiences, and attitudes of a culturally tailored cognitive behavioral therapy/motivational interviewing intervention for African American patients with type 2 diabetes: a randomized parallel design pilot study. Pilot and feasibility studies, 8 (1), 107.
[7] LaMoia, T. E., & Shulman, G. I. (2021). Cellular and Molecular Mechanisms of Metformin Action. Endocrine reviews, 42 (1), 77 – 96.
[8] Apostolova, N., Iannantuoni, F., Gruevska, A., Muntane, J., Rocha, M., & Victor, V. M. (2020). Mechanisms of action of metformin in type 2 diabetes: Effects on mitochondria and leukocyte-endothelium interactions. Redox biology, 34, 101517.
[9] Nasri, H., & Rafieian-Kopaei, M. (2014). Metformin: Current knowledge. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences, 19 (7), 658 – 664.
[10] Petersons C. J. (2018). Second steps in managing type 2 diabetes. Australian prescriber, 41 (5), 141 – 144.
[11] Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014). Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell metabolism, 20 (4), 573 – 591.
[12] Giorgino, F., Vora, J., Fenici, P., & Solini, A. (2020). Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovascular diabetology, 19 (1), 196.
[13] King, A., Tan, X., Dhopeshwarkar, N., Bohn, R., Dea, K., Leonard, C. E., & Havenon, A. de. (2025). Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease. American Journal of Preventive Cardiology, 21, 100922 – 100922.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Academic Journal of Science and Technology
This work is licensed under a Creative Commons Attribution 4.0 International License.
